A new in vivo pharmacokinetic recall study involving 114 participants in the Estonian Biobank has provided the first clinical ...

Internationally recognized leaders in inflammatory bowel disease bring deep expertise spanning ulcerative colitis, Crohn's ...

Appointments strengthen Palisade Bio's clinical strategy as PALI-2108 advances toward Phase 2 development in ulcerative colitis and fibrostenotic Crohn's disease, with a Phase 2 UC IND submission ...

Nuance Pharma ("Nuance") today announced that the National Medical Products Administration (NMPA) of China has officially accepted for review the New Drug Application (NDA) for Ohtuvayre® ...

Detailed price information for Palisade Bio Inc (PALI-Q) from The Globe and Mail including charting and trades.

Psoriatic arthritis is an autoimmune condition that causes joint inflammation, skin symptoms, and pain. People searching for psoriatic arthritis prescriptions are often looking for detailed ...

For a plaque psoriasis drug to succeed in a clinical trial, it doesn’t need to clear all of the redness and other signs of the inflammatory skin disease. But complete skin clearance is a benchmark ...

A radical strategy to tackle drug-resistant tuberculosis could involve reprogramming the metabolism of immune cells called macrophages. This approach makes the bacteria they harbour more sensitive to ...

Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026 If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in ...

A PDUFA target date of June 29, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for roflumilast cream 0.3% for ...